Corient Private Wealth
TLSI icon

Corient Private Wealth’s TriSalus Life Sciences TLSI Stock Holding History

Corient Private Wealth’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$364K Buy
+91,000
New +$446K ﹤0.01% 2215
2025
Q4 		– Sell
-75,700
Closed -$352K – 2835
2025
Q3 		$352K Buy
+75,700
New +$354K ﹤0.01% 2022

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Corient Private Wealth's TLSI Position: Q1 2026 in Review

Corient Private Wealth opened a new position in TriSalus Life Sciences (TLSI) in Q1 2026: 91,000 shares worth $364K. The stake represents ﹤0.01% of the portfolio and ranks #2215 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in TLSI as recently as Q3 2025.

Corient Private Wealth first reported a position in TLSI in Q3 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

  • Corient Private Wealth held 91,000 shares of TriSalus Life Sciences worth $364K as of Q1 2026.
  • TriSalus Life Sciences was a new Corient Private Wealth position in Q1 2026.
  • TriSalus Life Sciences made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2215 holding.
  • Corient Private Wealth first reported a position in TriSalus Life Sciences in Q3 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.